Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

OBJECTIVE: To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Fleischmann, Roy, van Adelsberg, Janet, Lin, Yong, Castelar‐Pinheiro, Geraldo da Rocha, Brzezicki, Jan, Hrycaj, Pawel, Graham, Neil M. H., van Hoogstraten, Hubert, Bauer, Deborah, Burmester, Gerd R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207906/
https://ncbi.nlm.nih.gov/pubmed/27860410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados